Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420015 · ClinicalTrials.gov registry record · Phase 4
Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT02420015 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 35 participants.
The verdict
NCT02420015, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.
Interventions
- DRUG Bupropion
- DRUG Nicotine replacement therapy
- BEHAVIORAL Mobile Contingency Management
- BEHAVIORAL cognitive-behavioral smoking cessation counseling
- BEHAVIORAL Stay Quit Coach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2019-01-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420015
The ClinicalTrials.gov registry entry for NCT02420015 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bupropion is the first listed.
NCT02420015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420015 about?
NCT02420015 is a clinical study titled "Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia". This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.
What is the current status of trial NCT02420015?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2017-03-27. Estimated completion is 2019-01-24.
What interventions are being tested in trial NCT02420015?
The interventions under investigation include: Bupropion (DRUG), Nicotine replacement therapy (DRUG), Mobile Contingency Management (BEHAVIORAL), cognitive-behavioral smoking cessation counseling (BEHAVIORAL), Stay Quit Coach (BEHAVIORAL).
Who is sponsoring clinical trial NCT02420015?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.